Organon Reports Results for the First Quarter Ended March 31, 2026

4/30/26 7:30:00 AM ET

$OGN

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $OGN alert in real time by email

First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency.
First quarter 2026 diluted earnings per share of $0.55 and non-GAAP Adjusted diluted earnings per share of $0.71.
First quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of $415 million, representing an Adjusted EBITDA margin of 28.4%.
On April 26, 2026, the company announced its pending merger into Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, "Sun Pharma") in an all-cash transaction (the "merger"). The merger is expected to close in early 2027, subject to customary closing conditions, including receipt of required regulatory approvals and approval by Organon stockholders.
In light of the pending merger, Organon will not be providing financial guidance or hosting quarterly earnings calls.

Organon (NYSE:OGN) today announced its results for the first quarter ended March 31, 2026.

First Quarter 2026 Revenue

in $ millions	Q1 2026		Q1 2025		VPY	VPY ex-FX
Women's Health	$	389	$	463	(16)%	(19)%
General Medicines
Biosimilars		173		141	23%	21%
Established Brands		880		887	(1)%	(7)%
Other ⁽¹⁾		18		22	(15)%	(21)%
Revenue	$	1,460	$	1,513	(4)%	(9)%

^{Totals may not foot due to rounding and percentages are computed using unrounded amounts.}
^{(1) Other includes manufacturing sales to third parties.}

For the first quarter of 2026, total revenue was $1.460 billion, down 4% on an as-reported basis and down 9% excluding the impact of foreign currency (ex-FX), compared with the first quarter of 2025.

Women's Health revenue declined 16% as-reported and declined 19% ex-FX in the first quarter of 2026, compared with the first quarter of 2025.

Sales of Nexplanon® (etonogestrel implant) decreased 21% ex-FX in the first quarter compared with the first quarter of 2025. In the U.S., sales of Nexplanon declined 28% primarily due to both decreased physician demand following the five-year label approval which as expected, has delayed reinsertions; and continued uncertainty around federal funding. Outside of the U.S., Nexplanon sales declined 4% ex-FX, due to the timing of shipments in selective emerging markets, partially offset by increased demand and access in Brazil.
Sales of oral contraceptives Marvelon^TM(desogestrel and ethinyl estradiol pill) and Mercilon^TM(desogestrel and ethinyl estradiol pill) declined 36% ex-FX in the first quarter of 2026 primarily due to decreased demand and market contraction in China and the timing of shipments in Asia Pacific.
Global Fertility revenue was down 9% ex-FX as a result of competition-driven price reductions in the U.S. partially offset by modest market growth in China.
In January of 2026 the company completed the sale of the Jada® system to Laborie.

Biosimilars revenue increased 23% as-reported and 21% ex-FX in the first quarter of 2026, compared with the first quarter of 2025, primarily due to the strong performance of Hadlima® (adalimumab-bwwd) associated with stronger demand in the U.S., and increased demand in Puerto Rico. Biosimilars also benefitted from contribution from new assets, Bildyos® (denosumab-nxxp) and Bilprevda® (denosumab-nxxp) which were approved by the U.S. Food and Drug Administration ("FDA") in the third quarter of 2025, and Tofidence® (tocilizumab-bavi), which the company acquired in the second quarter of 2025.

Established Brands revenue declined 1% as-reported and declined 7% ex-FX in the first quarter of 2026. Revenue contribution from Emgality®⁽¹⁾(galcanezumab-gnlm) partially offset a decline in the respiratory portfolio, which was driven by pricing pressure, as well as volume declines related to the adoption of revised medical guidelines that deprioritize the use of montelukast, including Singulair® (montelukast sodium), in various international markets, most recently, in China. Global sales of Dulera® (mometasone furoate and formoterol fumarate dihydrate) also declined in the first quarter of 2026 primarily due to pricing pressure and decreased demand in the U.S. VTAMA® (tapinarof) grew modestly in the first quarter of 2026 compared with the first quarter of 2025.

^{(1) Organon acquired certain European licensing and distribution rights to Emgality from Eli Lilly and Company ("Eli Lilly") beginning in early 2024. Emgality is a registered trademark of Eli Lilly in the European Union and other countries (used under license).}

First Quarter 2026 Profitability

in $ millions, except per share amounts	Q1 2026		Q1 2025		VPY
Revenues	$	1,460	$	1,513	(4)%
Cost of sales		677		672	1%
Gross profit		783		841	(7)%
Non-GAAP Adjusted gross profit ⁽¹⁾		861		934	(8)%
Net income		146		87	68%
Non-GAAP Adjusted net income ⁽¹⁾		188		265	(29)%
Diluted Earnings per Share (EPS)		0.55		0.33	67%
Non-GAAP Adjusted diluted EPS ⁽¹⁾		0.71		1.02	(30)%
Acquired in-process research & development (IPR&D) and milestones		—		6	NM
Adjusted EBITDA (Non-GAAP) ⁽¹⁾		415		484	(14)%

	Q1 2026		Q1 2025
Gross margin		53.6 %		55.6 %
Non-GAAP Adjusted gross margin ⁽¹⁾		59.0 %		61.7 %
Adjusted EBITDA margin (Non-GAAP) ^{(1, 2)}		28.4 %		32.0 %

^{(1) See Tables 4 and 5 for reconciliations of GAAP to non-GAAP financial measures.}

Reported gross margin in the first quarter of 2026 was 53.6% compared with 55.6% in the prior year period. Non-GAAP Adjusted gross margin was 59.0% in the first quarter of 2026, compared to 61.7% in the first quarter of 2025. Unfavorable pricing and product mix as well as foreign exchange rates were notable drivers in the decline of both reported gross margin and non-GAAP Adjusted gross margin.

Net income for the first quarter of 2026 was $146 million, or $0.55 per diluted share, compared with net income of $87 million, or $0.33 per diluted share, in the first quarter of 2025. For the first quarter of 2026, non-GAAP Adjusted net income was $188 million, or $0.71 per diluted share, compared with $265 million, or $1.02 per diluted share, for the first quarter of 2025.

Non-GAAP Adjusted EBITDA margin was 28.4% in the first quarter of 2026 compared with 32.0% in the first quarter of 2025. The year-over-year decline was primarily driven by a decrease in Adjusted Gross Margin.

Capital Allocation

Today, Organon's Board of Directors declared a quarterly dividend of $0.02 for each issued and outstanding share of the company's common stock. The dividend is payable on June 11, 2026, to stockholders of record at the close of business on May 11, 2026.

As of March 31, 2026, cash and cash equivalents were $1.12 billion, and debt was $8.57 billion.

Webcast Information

As is customary during the pendency of an acquisition, Organon has suspended its quarterly earnings calls and will not host a conference call in conjunction with today's first quarter earnings release.

About Organon

Organon (NYSE:OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women's Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets.

Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at http://www.organon.com and follow us on LinkedIn, Instagram, X, YouTube, TikTok and Facebook.

Cautionary Note Regarding Non-GAAP Financial Measures

This press release contains "non-GAAP financial measures," which are financial measures that either exclude or include amounts that are correspondingly not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles ("GAAP"). Specifically, the company makes use of the non-GAAP financial measures Adjusted EBITDA, Adjusted EBITDA margin, Adjusted gross margin, Adjusted gross profit, Adjusted net income, Adjusted EPS, and Adjusted diluted EPS, which are not recognized terms under GAAP and are presented only as a supplement to the company's GAAP financial statements. This press release also provides certain measures that exclude the impact of foreign exchange. We calculate foreign exchange by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results. The company believes that these non-GAAP financial measures help to enhance an understanding of the company's financial performance. However, the presentation of these measures has limitations as an analytical tool and should not be considered in isolation, or as a substitute for the company's results as reported under GAAP. Because not all companies use identical calculations, the presentations of these non-GAAP measures may not be comparable to other similarly titled measures of other companies. Please refer to Table 4 and Table 5 of this press release for additional information, including relevant definitions and reconciliations of non-GAAP financial measures contained herein to the most directly comparable GAAP measures.

The company's management uses the non-GAAP financial measures described above to evaluate the company's performance and to guide operational and financial decision making. Further, the company's management believes that these non-GAAP financial measures, which exclude certain items, help to enhance its ability to meaningfully communicate its underlying business performance, financial condition and results of operations.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, this press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the merger, including the anticipated timing of completion thereof. Forward-looking statements may be identified by words such as "proposed," "will," "continue," "expects," "believes," "estimates," "opportunity," "pursue," "anticipate," "be able to," "intend," or words of similar meaning. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to uncertainties as to the timing of the merger; the risk that the merger may not be completed on the anticipated terms in a timely manner or at all; the failure to satisfy any of the conditions to the consummation of the merger, including receiving, on a timely basis or otherwise, the minimum vote required by Organon's stockholders to approve the merger; the possibility that competing offers or acquisition proposals for Organon will be made; the possibility that any or all of the various conditions to the consummation of the merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive agreement, including in circumstances which would require Organon to pay a termination fee; the effect of the announcement or pendency of the merger on Organon's ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, or its operating results and business generally; risks related to diverting management's attention from Organon's ongoing business operations; the risk that stockholder litigation in connection with the merger may result in significant costs of defense, indemnification and liability; certain restrictions during the pendency of the merger that may impact Organon's ability to pursue certain business opportunities or strategic transactions; the risk that any announcements relating to the merger could have adverse effects on the market price of Organon's common stock, including if the merger is not consummated; risks that the benefits of the merger are not realized when and as expected; and legislative, regulatory and economic developments.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's filings with the SEC, including the company's most recent Annual Report on Form 10-K, Current Report on Form 8-K, filed by the company on April 27, 2026, and other SEC filings, available at the SEC's Internet site (www.sec.gov).

Additional Information and Where to Find It

This press release may be deemed to be solicitation material in respect of the proposed merger. In connection with the merger, Organon intends to file relevant materials with the SEC, including Organon's proxy statement in preliminary and definitive form on Schedule 14A (the "Merger Proxy Statement"). Organon will mail the Merger Proxy Statement and a proxy card to its stockholders in connection with the merger.

INVESTORS AND STOCKHOLDERS OF ORGANON ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING THE MERGER PROXY STATEMENT (WHEN THEY ARE AVAILABLE), BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT ORGANON, SUN PHARMA AND THE MERGER AND RELATED MATTERS. Investors and stockholders of Organon are or will be able to obtain these documents (when they are available) free of charge from the SEC's website at www.sec.gov, or through the investor relations section of Organon's website, https://www.organon.com.

Participants in the Solicitation

Organon and its directors, executive officers and other members of management and employees, under SEC rules, may be deemed to be "participants" in the solicitation of proxies from stockholders of Organon in favor of the proposed acquisition. Information about Organon's directors and executive officers is set forth in the 2026 Annual Meeting Proxy Statement, filed with the SEC on April 24, 2026, and which is available at https://www.sec.gov/ix?doc=/Archives/edgar/data/0001821825/000119312526177411/ogn-20260423.htm. To the extent holdings of Organon's securities by its directors or executive officers have changed since the amounts set forth in the 2026 Annual Meeting Proxy Statement, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC, which are available at https://www.sec.gov/edgar/browse/?CIK=1821825. Additional information concerning the interests of Organon's participants in the solicitation, which may, in some cases, be different than those of Organon's stockholders generally, will be set forth in the Merger Proxy Statement when it becomes available.

TABLE 1

Organon & Co.
Condensed Consolidated Statement of Income
(Unaudited, $ in millions except shares in thousands and per share amounts)

	Three Months Ended March 31,
	2026			2025
Revenues	$	1,460		$	1,513
Cost of sales		677			672
Gross Profit		783			841

Selling, general and administrative		424			420
Research and development		93			96
Acquired in-process research and development and milestones		—			6
Restructuring costs		31			86
Interest expense		111			124
Exchange losses (gains)		7			(4	)
Other (income) expense, net		(96	)		12
Income before income taxes		213			101
Income tax expense		67			14
Net income	$	146		$	87

Earnings per share:
Basic	$	0.56		$	0.34
Diluted	$	0.55		$	0.33

Weighted average shares outstanding:
Basic		260,370			257,862
Diluted		262,896			261,001

TABLE 2

Organon & Co.
Sales by top products
(Unaudited, $ in millions)

	Three Months Ended March 31,
	2026						2025
($ in millions)	U.S.		Int'l		Total		U.S.		Int'l		Total
Women's Health
Nexplanon/Implanon NXT	$	127	$	74	$	201	$	176	$	72	$	248
Follistim AQ		21		39		61		35		34		69
NuvaRing		6		18		24		6		16		22
Ganirelix Acetate Injection		2		24		26		5		23		27
Marvelon/Mercilon		—		26		26		—		39		39
Jada		5		—		5		15		—		15
Other Women's Health ⁽¹⁾		17		30		46		15		27		43
General Medicines
Biosimilars
Renflexis		42		15		57		44		12		57
Hadlima		51		16		67		33		14		47
Ontruzant		4		1		5		4		14		18
Brenzys		—		20		20		—		14		14
Other Biosimilars ⁽¹⁾		11		13		24		—		5		5
Established Brands
Cardiovascular
Atozet		—		85		85		—		77		77
Zetia		1		86		87		1		84		85
Cozaar/Hyzaar		2		55		57		2		53		55
Vytorin		1		20		21		1		22		23
Rosuzet		—		6		6		—		4		4
Other Cardiovascular ⁽¹⁾		1		27		28		—		30		30
Respiratory
Singulair		2		38		40		2		72		74
Nasonex		—		65		65		—		71		72
Dulera		23		12		35		34		10		43
Clarinex		1		30		31		—		34		34
Other Respiratory ⁽¹⁾		11		1		12		10		3		13
Non-Opioid Pain, Bone and Dermatology
Arcoxia		—		59		59		—		62		62
Fosamax		—		29		29		1		32		33
Diprospan		—		35		35		—		30		30
Vtama		23		2		25		20		4		24
Other Non-Opioid Pain, Bone and Dermatology ⁽¹⁾		3		65		68		4		65		68
Other
Propecia		1		28		30		1		24		26
Emgality		—		54		54		—		32		32
Proscar		—		26		26		—		24		24
Other ⁽¹⁾		3		85		87		3		76		78
Other ⁽²⁾		—		18		18		—		22		22
Revenues	$	358	$	1,102	$	1,460	$	412	$	1,101	$	1,513

^{Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies.}
^{(1) Includes sales of products not listed separately.}
^{(2) Other includes manufacturing sales to third parties.}

TABLE 3

Organon & Co.
Sales by geographic area
(Unaudited, $ in millions)

	Three Months Ended March 31,
	2026		2025
Europe and Canada	$	412	$	376
United States		358		412
Asia Pacific and Japan		226		251
China		194		204
Latin America, Middle East, Russia, and Africa		247		240
Other ⁽¹⁾		23		30
Revenues	$	1,460	$	1,513

^{(1) Other includes manufacturing sales to third parties.}

TABLE 4

Organon & Co.
Reconciliation of GAAP Reported to Non-GAAP Adjusted Metrics
(Unaudited, $ in millions)

	Three Months Ended March 31,
	2026			2025
GAAP Gross Profit	$	783		$	841
Adjusted for:
Manufacturing network costs ⁽¹⁾		21			29
Stock-based compensation		3			4
Amortization		47			50
Acquisition-related costs ⁽²⁾		7			9
Other		—			1
Adjusted Non-GAAP Gross Profit	$	861		$	934

^{(1) Manufacturing network related costs include costs from exiting manufacturing and supply agreements with Merck & Co., Inc., Rahway NJ, US. For additional details refer to Table 5.}
^{(2) Acquisition-related costs relate to costs from the acquisition of Dermavant. For additional details refer to Table 5.}

	Three Months Ended March 31,
	2026			2025
GAAP Gross Margin		53.6	%		55.6	%
Total impact of Non-GAAP adjustments		5.4	%		6.1	%
Adjusted Non-GAAP Gross Margin		59.0	%		61.7	%

	Three Months Ended March 31,
	2026			2025
GAAP Selling, general and administrative expenses	$	424		$	420
Adjusted for:
Stock-based compensation		(13	)		(16	)
Restructuring related charges		—			(6	)
Other		(13	)		(3	)
Adjusted Non-GAAP Selling, general and administrative expenses	$	398		$	395

TABLE 4

Organon & Co.
Reconciliation of GAAP Reported to Non-GAAP Adjusted Metrics (Continued)
(Unaudited, $ in millions except per share amounts)

	Three Months Ended March 31,
	2026			2025
GAAP Research and development expenses	$	93		$	96
Adjusted for:
Manufacturing network costs⁽¹⁾		(3	)		(3	)
Stock-based compensation		(3	)		(4	)
Other		(1	)		(1	)
Adjusted Non-GAAP Research and development expenses	$	86		$	88

^{(1) Manufacturing network related costs include costs from exiting manufacturing and supply agreements with Merck & Co., Inc., Rahway NJ, US. For additional details refer to Table 5.}

	Three Months Ended March 31,
	2026			2025
GAAP Reported Net Income	$	146		$	87
Adjusted for:
Cost of sales adjustments		78			93
Selling, general and administrative adjustments		26			25
Research and development adjustments		7			8
Jada divestiture		(81	)		—
Restructuring		31			86
Change in fair value of contingent consideration		(5	)		11
Other (gain) expense, net		(3	)		4
Tax impact on adjustments above⁽¹⁾		(11	)		(49	)
Non-GAAP Adjusted Net Income	$	188		$	265

^{(1) For the three months ended March 31, 2026 and 2025, the GAAP income tax rates were 31.4% and 13.4%, respectively, and the non-GAAP income tax rates were 29.3% and 19.2%, respectively. These adjustments represent the estimated tax impacts on the reconciling items by applying the statutory rate and applicable law of the originating territory of the non-GAAP adjustments.}

	Three Months Ended March 31,
	2026			2025
GAAP Diluted Earnings per Share	$	0.55		$	0.33
Total impact of Non-GAAP adjustments		0.16			0.69
Non-GAAP Adjusted Diluted Earnings per Share	$	0.71		$	1.02

TABLE 5

Organon & Co.
Reconciliation of GAAP Net (Loss) Income to Non-GAAP Adjusted EBITDA
(Unaudited, $ in millions)

	Three Months Ended March 31,
	2026			2025
GAAP Reported Net Income	$	146		$	87
Depreciation ⁽¹⁾		38			32
Amortization		47			50
Interest expense		111			124
Income tax expense (benefit)		67			14
EBITDA (Non-GAAP)	$	409		$	307
Restructuring and related charges		31			92
Manufacturing network related ⁽²⁾		27			36
Acquisition-related costs ⁽³⁾		7			9
Change in contingent consideration		(5	)		11
Jada divestiture		(81	)		—
Other costs		8			5
Stock-based compensation		19			24
Adjusted EBITDA (Non-GAAP)	$	415		$	484
Adjusted EBITDA margin (Non-GAAP)		28.4	%		32.0	%

^{(1) Excludes accelerated depreciation included in one-time costs.}
^{(2) Manufacturing network related costs, including exiting of temporary manufacturing and supply agreements with Merck & Co., Inc., Rahway, NJ, US, reflect accelerated depreciation, exit premiums, technology transfer costs, stability and qualification batch costs, and third-party contractor costs.}
^{(3) Acquisition related costs for the three months ended March 31, 2026 and 2025, reflect the amortization pertaining to the fair value inventory purchase accounting adjustment for the Dermavant transaction.}
^{As the costs described in (1) through (3) above are directly related to the separation of Organon and acquisition related activities and therefore arise from a one-time event outside of the ordinary course of the company's operations, the adjustment of these items provides meaningful, supplemental, information that the company believes will enhance an investor's understanding of the company's ongoing operating performance.}

View source version on businesswire.com: https://www.businesswire.com/news/home/20260430180575/en/

Media Contacts:

Felicia Bisaro

(646) 703-1807

Kate Vossen

(732) 675-8448

Investor Contacts:

Jennifer Halchak

(201) 275-2711

Renee McKnight

(551) 204-6129

Get the next $OGN alert in real time by email

Recent Analyst Ratings for

$OGN

Date	Price Target	Rating	Analyst
4/28/2026	$14.00	Underweight → Neutral	Piper Sandler
12/9/2025	$7.50	Underweight	Barclays
10/27/2025	$5.00	Overweight → Underweight	Piper Sandler
5/2/2025		Outperform → In-line	Evercore ISI
9/6/2024	$18.00 → $20.00	Neutral → Underweight	JP Morgan
11/3/2023	$33.00 → $16.00	Buy → Neutral	Goldman
9/21/2023	$28.00	Overweight	Barclays
3/16/2023	$33.00	Outperform	Raymond James

More analyst ratings

Organon Reports Results for the First Quarter Ended March 31, 2026

4/30/26 7:30:00 AM ET

$OGN

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $OGN alert in real time by email

First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency.
First quarter 2026 diluted earnings per share of $0.55 and non-GAAP Adjusted diluted earnings per share of $0.71.
First quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of $415 million, representing an Adjusted EBITDA margin of 28.4%.
On April 26, 2026, the company announced its pending merger into Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, "Sun Pharma") in an all-cash transaction (the "merger"). The merger is expected to close in early 2027, subject to customary closing conditions, including receipt of required regulatory approvals and approval by Organon stockholders.
In light of the pending merger, Organon will not be providing financial guidance or hosting quarterly earnings calls.

Organon (NYSE:OGN) today announced its results for the first quarter ended March 31, 2026.

First Quarter 2026 Revenue

in $ millions	Q1 2026		Q1 2025		VPY	VPY ex-FX
Women's Health	$	389	$	463	(16)%	(19)%
General Medicines
Biosimilars		173		141	23%	21%
Established Brands		880		887	(1)%	(7)%
Other ⁽¹⁾		18		22	(15)%	(21)%
Revenue	$	1,460	$	1,513	(4)%	(9)%

^{Totals may not foot due to rounding and percentages are computed using unrounded amounts.}
^{(1) Other includes manufacturing sales to third parties.}

For the first quarter of 2026, total revenue was $1.460 billion, down 4% on an as-reported basis and down 9% excluding the impact of foreign currency (ex-FX), compared with the first quarter of 2025.

Women's Health revenue declined 16% as-reported and declined 19% ex-FX in the first quarter of 2026, compared with the first quarter of 2025.

Sales of Nexplanon® (etonogestrel implant) decreased 21% ex-FX in the first quarter compared with the first quarter of 2025. In the U.S., sales of Nexplanon declined 28% primarily due to both decreased physician demand following the five-year label approval which as expected, has delayed reinsertions; and continued uncertainty around federal funding. Outside of the U.S., Nexplanon sales declined 4% ex-FX, due to the timing of shipments in selective emerging markets, partially offset by increased demand and access in Brazil.
Sales of oral contraceptives Marvelon^TM(desogestrel and ethinyl estradiol pill) and Mercilon^TM(desogestrel and ethinyl estradiol pill) declined 36% ex-FX in the first quarter of 2026 primarily due to decreased demand and market contraction in China and the timing of shipments in Asia Pacific.
Global Fertility revenue was down 9% ex-FX as a result of competition-driven price reductions in the U.S. partially offset by modest market growth in China.
In January of 2026 the company completed the sale of the Jada® system to Laborie.

First Quarter 2026 Profitability

in $ millions, except per share amounts	Q1 2026		Q1 2025		VPY
Revenues	$	1,460	$	1,513	(4)%
Cost of sales		677		672	1%
Gross profit		783		841	(7)%
Non-GAAP Adjusted gross profit ⁽¹⁾		861		934	(8)%
Net income		146		87	68%
Non-GAAP Adjusted net income ⁽¹⁾		188		265	(29)%
Diluted Earnings per Share (EPS)		0.55		0.33	67%
Non-GAAP Adjusted diluted EPS ⁽¹⁾		0.71		1.02	(30)%
Acquired in-process research & development (IPR&D) and milestones		—		6	NM
Adjusted EBITDA (Non-GAAP) ⁽¹⁾		415		484	(14)%

	Q1 2026		Q1 2025
Gross margin		53.6 %		55.6 %
Non-GAAP Adjusted gross margin ⁽¹⁾		59.0 %		61.7 %
Adjusted EBITDA margin (Non-GAAP) ^{(1, 2)}		28.4 %		32.0 %

^{(1) See Tables 4 and 5 for reconciliations of GAAP to non-GAAP financial measures.}

As of March 31, 2026, cash and cash equivalents were $1.12 billion, and debt was $8.57 billion.

Participants in the Solicitation

TABLE 1

Organon & Co.
Condensed Consolidated Statement of Income
(Unaudited, $ in millions except shares in thousands and per share amounts)

	Three Months Ended March 31,
	2026			2025
Revenues	$	1,460		$	1,513
Cost of sales		677			672
Gross Profit		783			841

Selling, general and administrative		424			420
Research and development		93			96
Acquired in-process research and development and milestones		—			6
Restructuring costs		31			86
Interest expense		111			124
Exchange losses (gains)		7			(4	)
Other (income) expense, net		(96	)		12
Income before income taxes		213			101
Income tax expense		67			14
Net income	$	146		$	87

Earnings per share:
Basic	$	0.56		$	0.34
Diluted	$	0.55		$	0.33

Weighted average shares outstanding:
Basic		260,370			257,862
Diluted		262,896			261,001

TABLE 2

Organon & Co.
Sales by top products
(Unaudited, $ in millions)

	Three Months Ended March 31,
	2026						2025
($ in millions)	U.S.		Int'l		Total		U.S.		Int'l		Total
Women's Health
Nexplanon/Implanon NXT	$	127	$	74	$	201	$	176	$	72	$	248
Follistim AQ		21		39		61		35		34		69
NuvaRing		6		18		24		6		16		22
Ganirelix Acetate Injection		2		24		26		5		23		27
Marvelon/Mercilon		—		26		26		—		39		39
Jada		5		—		5		15		—		15
Other Women's Health ⁽¹⁾		17		30		46		15		27		43
General Medicines
Biosimilars
Renflexis		42		15		57		44		12		57
Hadlima		51		16		67		33		14		47
Ontruzant		4		1		5		4		14		18
Brenzys		—		20		20		—		14		14
Other Biosimilars ⁽¹⁾		11		13		24		—		5		5
Established Brands
Cardiovascular
Atozet		—		85		85		—		77		77
Zetia		1		86		87		1		84		85
Cozaar/Hyzaar		2		55		57		2		53		55
Vytorin		1		20		21		1		22		23
Rosuzet		—		6		6		—		4		4
Other Cardiovascular ⁽¹⁾		1		27		28		—		30		30
Respiratory
Singulair		2		38		40		2		72		74
Nasonex		—		65		65		—		71		72
Dulera		23		12		35		34		10		43
Clarinex		1		30		31		—		34		34
Other Respiratory ⁽¹⁾		11		1		12		10		3		13
Non-Opioid Pain, Bone and Dermatology
Arcoxia		—		59		59		—		62		62
Fosamax		—		29		29		1		32		33
Diprospan		—		35		35		—		30		30
Vtama		23		2		25		20		4		24
Other Non-Opioid Pain, Bone and Dermatology ⁽¹⁾		3		65		68		4		65		68
Other
Propecia		1		28		30		1		24		26
Emgality		—		54		54		—		32		32
Proscar		—		26		26		—		24		24
Other ⁽¹⁾		3		85		87		3		76		78
Other ⁽²⁾		—		18		18		—		22		22
Revenues	$	358	$	1,102	$	1,460	$	412	$	1,101	$	1,513

^{Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies.}
^{(1) Includes sales of products not listed separately.}
^{(2) Other includes manufacturing sales to third parties.}

TABLE 3

Organon & Co.
Sales by geographic area
(Unaudited, $ in millions)

	Three Months Ended March 31,
	2026		2025
Europe and Canada	$	412	$	376
United States		358		412
Asia Pacific and Japan		226		251
China		194		204
Latin America, Middle East, Russia, and Africa		247		240
Other ⁽¹⁾		23		30
Revenues	$	1,460	$	1,513

^{(1) Other includes manufacturing sales to third parties.}

TABLE 4

Organon & Co.
Reconciliation of GAAP Reported to Non-GAAP Adjusted Metrics
(Unaudited, $ in millions)

	Three Months Ended March 31,
	2026			2025
GAAP Gross Profit	$	783		$	841
Adjusted for:
Manufacturing network costs ⁽¹⁾		21			29
Stock-based compensation		3			4
Amortization		47			50
Acquisition-related costs ⁽²⁾		7			9
Other		—			1
Adjusted Non-GAAP Gross Profit	$	861		$	934

^{(1) Manufacturing network related costs include costs from exiting manufacturing and supply agreements with Merck & Co., Inc., Rahway NJ, US. For additional details refer to Table 5.}
^{(2) Acquisition-related costs relate to costs from the acquisition of Dermavant. For additional details refer to Table 5.}

	Three Months Ended March 31,
	2026			2025
GAAP Gross Margin		53.6	%		55.6	%
Total impact of Non-GAAP adjustments		5.4	%		6.1	%
Adjusted Non-GAAP Gross Margin		59.0	%		61.7	%

	Three Months Ended March 31,
	2026			2025
GAAP Selling, general and administrative expenses	$	424		$	420
Adjusted for:
Stock-based compensation		(13	)		(16	)
Restructuring related charges		—			(6	)
Other		(13	)		(3	)
Adjusted Non-GAAP Selling, general and administrative expenses	$	398		$	395

TABLE 4

Organon & Co.
Reconciliation of GAAP Reported to Non-GAAP Adjusted Metrics (Continued)
(Unaudited, $ in millions except per share amounts)

	Three Months Ended March 31,
	2026			2025
GAAP Research and development expenses	$	93		$	96
Adjusted for:
Manufacturing network costs⁽¹⁾		(3	)		(3	)
Stock-based compensation		(3	)		(4	)
Other		(1	)		(1	)
Adjusted Non-GAAP Research and development expenses	$	86		$	88

^{(1) Manufacturing network related costs include costs from exiting manufacturing and supply agreements with Merck & Co., Inc., Rahway NJ, US. For additional details refer to Table 5.}

	Three Months Ended March 31,
	2026			2025
GAAP Reported Net Income	$	146		$	87
Adjusted for:
Cost of sales adjustments		78			93
Selling, general and administrative adjustments		26			25
Research and development adjustments		7			8
Jada divestiture		(81	)		—
Restructuring		31			86
Change in fair value of contingent consideration		(5	)		11
Other (gain) expense, net		(3	)		4
Tax impact on adjustments above⁽¹⁾		(11	)		(49	)
Non-GAAP Adjusted Net Income	$	188		$	265

^{(1) For the three months ended March 31, 2026 and 2025, the GAAP income tax rates were 31.4% and 13.4%, respectively, and the non-GAAP income tax rates were 29.3% and 19.2%, respectively. These adjustments represent the estimated tax impacts on the reconciling items by applying the statutory rate and applicable law of the originating territory of the non-GAAP adjustments.}

	Three Months Ended March 31,
	2026			2025
GAAP Diluted Earnings per Share	$	0.55		$	0.33
Total impact of Non-GAAP adjustments		0.16			0.69
Non-GAAP Adjusted Diluted Earnings per Share	$	0.71		$	1.02

TABLE 5

Organon & Co.
Reconciliation of GAAP Net (Loss) Income to Non-GAAP Adjusted EBITDA
(Unaudited, $ in millions)

	Three Months Ended March 31,
	2026			2025
GAAP Reported Net Income	$	146		$	87
Depreciation ⁽¹⁾		38			32
Amortization		47			50
Interest expense		111			124
Income tax expense (benefit)		67			14
EBITDA (Non-GAAP)	$	409		$	307
Restructuring and related charges		31			92
Manufacturing network related ⁽²⁾		27			36
Acquisition-related costs ⁽³⁾		7			9
Change in contingent consideration		(5	)		11
Jada divestiture		(81	)		—
Other costs		8			5
Stock-based compensation		19			24
Adjusted EBITDA (Non-GAAP)	$	415		$	484
Adjusted EBITDA margin (Non-GAAP)		28.4	%		32.0	%

^{(1) Excludes accelerated depreciation included in one-time costs.}
^{(2) Manufacturing network related costs, including exiting of temporary manufacturing and supply agreements with Merck & Co., Inc., Rahway, NJ, US, reflect accelerated depreciation, exit premiums, technology transfer costs, stability and qualification batch costs, and third-party contractor costs.}
^{(3) Acquisition related costs for the three months ended March 31, 2026 and 2025, reflect the amortization pertaining to the fair value inventory purchase accounting adjustment for the Dermavant transaction.}
^{As the costs described in (1) through (3) above are directly related to the separation of Organon and acquisition related activities and therefore arise from a one-time event outside of the ordinary course of the company's operations, the adjustment of these items provides meaningful, supplemental, information that the company believes will enhance an investor's understanding of the company's ongoing operating performance.}

View source version on businesswire.com: https://www.businesswire.com/news/home/20260430180575/en/

Media Contacts:

Felicia Bisaro

(646) 703-1807

Kate Vossen

(732) 675-8448

Investor Contacts:

Jennifer Halchak

(201) 275-2711

Renee McKnight

(551) 204-6129

Get the next $OGN alert in real time by email

Recent Analyst Ratings for

$OGN

Date	Price Target	Rating	Analyst
4/28/2026	$14.00	Underweight → Neutral	Piper Sandler
12/9/2025	$7.50	Underweight	Barclays
10/27/2025	$5.00	Overweight → Underweight	Piper Sandler
5/2/2025		Outperform → In-line	Evercore ISI
9/6/2024	$18.00 → $20.00	Neutral → Underweight	JP Morgan
11/3/2023	$33.00 → $16.00	Buy → Neutral	Goldman
9/21/2023	$28.00	Overweight	Barclays
3/16/2023	$33.00	Outperform	Raymond James

More analyst ratings

Organon Reports Results for the First Quarter Ended March 31, 2026

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$OGN

Organon Reports Results for the First Quarter Ended March 31, 2026

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$OGN

$OGN
Insider Purchases

SVP and Corporate Controller Holzbaur Lynette bought $353,080 worth of shares (26,448 units at $13.35), increasing direct ownership by 100% to 52,851 units (SEC Form 4)

Executive Chair Cox Carrie Smith bought $501,755 worth of shares (65,400 units at $7.67) (SEC Form 4)

Director Cox Carrie Smith bought $100,591 worth of shares (12,469 units at $8.07) (SEC Form 4)

$OGN
Press Releases

Organon to Present New Research on Access and Value at ISPOR 2026